Thank you very much for the question. There are maybe just a couple of quick things. I will try to be very brief.
In my reference to October 2020, the strategy was to identify, following expert scientific advice, which candidate vaccines had the greatest promise to come to market safely and effectively. Canada made a series of investments across a diversity of platforms including Moderna, Pfizer, Medicago and Novavax. Canada invested in a portfolio of vaccines and we're seeing the results of those investments play out today.
In terms of your question about investment priorities going forward, many of those are articulated directly in the strategy. We will continue to see investments made upstream in R and D and in talent. We will see investments made to continue to build out our industrial capacity across protein-based vaccines, mRNA vaccines and viral vector vaccines. You will see investment in development of therapeutics and antibody therapies as well as supply chain investments.
We still have quite a bit of work to do to continue down this path to rebuild the sector, guided by the strategy, and to strategically build out the ecosystem that is described in the document that was published last summer.